EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

SIRT2 inhibition protects against cardiac hypertrophy and ischemic injury

Xiaoyan Yang iD, Hsiang-Chun Chang, Yuki Tatekoshi, Amir Mahmoodzadeh iD, Maryam Balibegloo, Zeinab Najafi, Rongxue Wu, Chunlei Chen, Tatsuya Sato iD, Jason Shapiro iD, Hossein Ardehali iD

eLife · 20.09.2023 · 12

DOI: 10.7554/elife.85571 ↗

Kurz gefasst

Fachartikel in der Zeitschrift eLife, online erschienen am 20.09.2023. Verfasst von Xiaoyan Yang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Feinberg Cardiovascular and Renal Research Institute, Northwestern University School of Medicine, Chicago, United States. Hauptthemen laut MEDLINE: NF-E2-Related Factor 2, Sirtuin 2. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, National Institutes of Health, Leducq.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sirtuins (SIRT) exhibit deacetylation or ADP-ribosyltransferase activity and regulate a wide range of cellular processes in the nucleus, mitochondria, and cytoplasm. The role of the only sirtuin that resides in the cytoplasm, SIRT2, in the development of ischemic injury and cardiac hypertrophy is not known. In this paper, we show that the hearts of mice with deletion of Sirt2 ( Sirt2 -/- ) display improved cardiac function after ischemia-reperfusion (I/R) and pressure overload (PO), suggesting that SIRT2 exerts maladaptive effects in the heart in response to stress. Similar results were obtained in mice with cardiomyocyte-specific Sirt2 deletion. Mechanistic studies suggest that SIRT2 modulates cellular levels and activity of nuclear factor (erythroid-derived 2)-like 2 (NRF2), which results in reduced expression of antioxidant proteins. Deletion of Nrf2 in the hearts of Sirt2 -/- mice reversed protection after PO. Finally, treatment of mouse hearts with a specific SIRT2 inhibitor reduced cardiac size and attenuates cardiac hypertrophy in response to PO. These data indicate that SIRT2 has detrimental effects in the heart and plays a role in cardiac response to injury and the progression of cardiac hypertrophy, which makes this protein a unique member of the SIRT family. Additionally, our studies provide a novel approach for treatment of cardiac hypertrophy and injury by targeting SIRT2 pharmacologically, providing a novel avenue for the treatment of these disorders.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NF-E2-Related Factor 2Sirtuin 2AnimalsMiceCardiomegalyIschemiaMyocytes, Cardiac

Stichwörter der Autor:innen

cardiac hypertrophyheart failuremedicinemousesirtuins

Substanzen

NF-E2-Related Factor 2Sirtuin 2Sirt2 protein, mouse

Autor:innen und Institutionen

  • Feinberg Cardiovascular and Renal Research Institute, Northwestern University School of Medicine, Chicago, United States.

ORCID-Profile: Xiaoyan Yang, Amir Mahmoodzadeh, Tatsuya Sato, Jason Shapiro, Hossein Ardehali

Förderung

  • NHLBI NIH HHS
  • National Institutes of Health
  • Leducq
  • American Heart Association

Zitieren

APA

Yang, X., Chang, H. C., Tatekoshi, Y., Mahmoodzadeh, A., Balibegloo, M., Najafi, Z., Wu, R., Chen, C., Sato, T., Shapiro, J., & Ardehali, H. (2023). SIRT2 inhibition protects against cardiac hypertrophy and ischemic injury. eLife, 12. https://doi.org/10.7554/elife.85571

Vancouver

Yang X, Chang HC, Tatekoshi Y, Mahmoodzadeh A, Balibegloo M, Najafi Z, et al. SIRT2 inhibition protects against cardiac hypertrophy and ischemic injury. eLife. 2023;12. doi:10.7554/elife.85571

BibTeX
@article{Yang2023,
  author = {Yang, Xiaoyan and Chang, Hsiang-Chun and Tatekoshi, Yuki and Mahmoodzadeh, Amir and Balibegloo, Maryam and Najafi, Zeinab and Wu, Rongxue and Chen, Chunlei and Sato, Tatsuya and Shapiro, Jason and Ardehali, Hossein},
  title = {SIRT2 inhibition protects against cardiac hypertrophy and ischemic injury},
  journal = {eLife},
  year = {2023},
  volume = {12},
  doi = {10.7554/elife.85571}
}
Kostenlos starten →